Factors Associated With Outcomes and Response to Therapy in Patients With Infiltrative Hepatocellular Carcinoma Neil Mehta, Nicholas Fidelman, Monika Sarkar, Francis Y. Yao Clinical Gastroenterology and Hepatology Volume 11, Issue 5, Pages 572-578 (May 2013) DOI: 10.1016/j.cgh.2012.12.030 Copyright © 2013 AGA Institute Terms and Conditions
Figure 1 Typical appearance of iHCC (A). Coronal cross-sectional image demonstrating large, ill-defined iHCC in right hepatic lobe (B). On angiogram, this lesion demonstrates minimal hypervascularity (C). After TACE, the angiogram demonstrates only patchy and diffuse ethiodized oil uptake. Clinical Gastroenterology and Hepatology 2013 11, 572-578DOI: (10.1016/j.cgh.2012.12.030) Copyright © 2013 AGA Institute Terms and Conditions
Figure 2 Kaplan–Meier survival curve for iHCC patients treated with (A) TACE vs no therapy and (B) sorafenib vs no therapy. Clinical Gastroenterology and Hepatology 2013 11, 572-578DOI: (10.1016/j.cgh.2012.12.030) Copyright © 2013 AGA Institute Terms and Conditions